Atlas Trials

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Clinical trial NCT04071457 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04071457
Sponsor
SWOG Cancer Research Network
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2019-08-13
Primary completion
2029-07-01
Enrollment
1100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.